Thirst intensity survey in ADPKD patients

Clin Exp Nephrol. 2023 Oct;27(10):819-827. doi: 10.1007/s10157-023-02373-7. Epub 2023 Jun 23.

Abstract

Introduction: With increased fluid intake and tolvaptan treatment, the growth rate of cysts can be theoretically decelerated in autosomal polycystic kidney disease. In this prospective study, it was planned to evaluate thirst sensation in these patients and the parameters affecting its intensity.

Methods: Forty-one ADPKD patients on tolvaptan and 40 ADPKD patients not on tolvaptan as the control group were evaluated for thirst distress sensation and intensity. The feeling of thirst and the discomfort caused by excessive fluid intake was assessed with Thirst Distress Scale-HF 12 questions (60/12). Thirst intensity was evaluated with a 100 mm visual scale.

Results: Of the whole group, 35.8% (29) were males, and 64.2% (52) were females. The mean age of the tolvaptan group was 39.17 ± 9.35 years and for the control group, it was 41.95 ± 12.29 years. There was a negative correlation between the thirst distress score of the patients and an increase in creatinine level after a year of tolvaptan treatment (r = - 0.335, p = 0.035). The patients not taking thiazide had higher thirst intensity scores (p = 0.004). There was no impact of tolvaptan dosage, total kidney volume, serum sodium, urinary osmolarity or eGFR on thirst distress and thirst intensity scores.

Discussion/conclusion: Only thiazide co-treatment had a positive impact on thirst distress and intensity when given tolvaptan. Thirst Distress Scale for ADPKD patients can be used to classify patients before and during tolvaptan treatment.

Keywords: ADPKD; Thirst sensation and intensity; Tolvaptan.

MeSH terms

  • Adult
  • Antidiuretic Hormone Receptor Antagonists
  • Female
  • Humans
  • Male
  • Middle Aged
  • Polycystic Kidney, Autosomal Dominant* / drug therapy
  • Prospective Studies
  • Thirst
  • Tolvaptan / therapeutic use

Substances

  • Tolvaptan
  • Antidiuretic Hormone Receptor Antagonists